Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

about

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments.

P2860

Q47552016-2FE77469-36F5-4A93-9970-4E0605C7F75C

P2860

Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

Item

http://www.wikidata.org/entity/Q38840646

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Recent advances in the biologi ...... n pitfalls in clinical trials.

@en

type

Item

label

Recent advances in the biologi ...... n pitfalls in clinical trials.

@en

prefLabel

Recent advances in the biologi ...... n pitfalls in clinical trials.

@en

P1476

Recent advances in the biologi ...... on pitfalls in clinical trials

@en

P2093

Ahmed T Moustafa

http://www.w3.org/2001/XMLSchema#string

Hanan Al-Rayes

http://www.w3.org/2001/XMLSchema#string

Jorge Medina-Rosas

http://www.w3.org/2001/XMLSchema#string

P2860

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus

Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.

Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Belimumab: review of use in systemic lupus erythematosus.

Data quality challenges in systemic lupus erythematosus trials: how can this be optimized?

P304

1225-1238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2016.1214263

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zahi Touma

P577

2016-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27429254

http://www.w3.org/2001/XMLSchema#string

Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

about

P2860

P2860

Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698